SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq.

Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration. Both programmes have also shown a high level of differentiation in early profiling and have the potential to produce best-in-class assets.

Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain.

Exscientia plc (Nasdaq: EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST).

Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2024, are summarised below.

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:EXAI),(NASDAQ:TWST),(NYSE:IQV) EQNX::TICKER_END

PALM BEACH, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The technological shift driven by the rise of artificial intelligence (AI) is giving patients in the USA cautious optimism towards the potential of generative AI in healthcare. In order to safely bring AI into the healthcare space, state governments across the USA are working on how to regulate its implementation. The potential to enhance accuracy and speed in diagnostics, analyzing eye scans and predicting complications, and even designing new drugs, the potential for AI in healthcare is too big to ignore. Reaching the goal of safely bringing AI into the medical space still requires lots of research and development, with several tech innovators recently updating the market with their latest developments, including: Avant Technologies Inc. (OTCQB: AVAI), Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), Exscientia plc (NASDAQ: EXAI), Twist Bioscience Corporation (NASDAQ: TWST) and IQVIA Holdings Inc. (NYSE: IQV).

Operational complementarities expected to yield annual synergies of approximately $100 million

Exscientia plc (Nasdaq: EXAI) today announced it has reached an agreement to acquire GT Apeiron’s share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property.

Exscientia plc (Nasdaq: EXAI) today announced it will be expanding its work with Amazon Web Services (AWS) to use the cloud provider’s artificial intelligence (AI) and machine learning (ML) services to power its platform for end-to-end drug discovery and automation.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc (“Exscientia” or “the Company”) (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

The Law Offices of Frank R. Cruz reminds investors of the upcoming June 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) securities between March 23, 2022 and February 12, 2024, inclusive (the “Class Period”).

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) --

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc (“Exscientia” or “the Company”) (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Exscientia plc. (“Exscientia” or the “Company”) (NASDAQ: EXAI) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Exscientia securities between March 23, 2022, and February 12, 2024, both dates inclusive (the “Class Period”). Investors have until June 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exscientia plc (“Exscientia” or the “Company”) (NASDAQ: EXAI) and reminds investors of the June 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) for violations of the federal securities laws on behalf of investors who purchased or acquired Exscientia common stock between March 23, 2022, and Febraury 12, 2024, inclusive (the “Class Period”).

LOS ANGELES, June 21, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc (“Exscientia” or “the Company”) (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) --

LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Exscientia plc (“Exscientia” or “the Company”) (NASDAQ: EXAI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of GoodRx Holdings, Inc. (NASDAQ: GDRX), Exscientia plc. (NASDAQ: EXAI), Malibu Boats, Inc. (NASDAQ: MBUU), and Equinix (NASDAQ: EQIX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) for violations of the federal securities laws on behalf of investors who purchased or acquired Exscientia common stock between March 23, 2022, and Febraury 12, 2024, inclusive (the “Class Period”).

NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Exscientia p.l.c. (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024. Exscientia p.l.c. describes itself as an “artificial intelligence (“AI”) driven Pharma-tech company that engages in the design and develop differentiated medicines for diseases with high unmet patient needs.”

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) for violations of the federal securities laws on behalf of investors who purchased or acquired Exscientia common stock between March 23, 2022, and Febraury 12, 2024, inclusive (the “Class Period”).